Lead text placeholder. Lorem ipsum dolor sit amet, consectetur adipisicing elit.

 

  • A Phase 2, Open-Label, Randomized Study to Assess the
  • Antitumor Activity and Safety of Zolbetuximab (IMAB362) in
  • Combination with Nab-Paclitaxel and Gemcitabine (Nab-P +
  • GEM) as First Line Treatment in Subjects with Claudin 18.2
  • (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma